Bioptigen Inc.
Technology company !%Bioptigen Inc.%! of Durham, N.C., has received clearance from Health Canada to begin marketing its handheld ophthalmic imaging systems for patient use. The Envisu series spectral domain ophthalmic imaging system uses low-power near-infrared light to produce high-resolution depth-resolved images of eye structures in real time. Based on OCT technology, the systems are expected to enable greater understanding of eye disease progression, detection and treatment. “Now that Bioptigen has regulatory approval to market our technology in Canada and the European Union, adults and children can begin benefiting from this flexible and detailed imaging platform that complements existing diagnostic techniques and treatments,” said Eric Buckland, president and CEO.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024